Sona Shah1, Laura Boucai1. 1. Department of Medicine, Division of Endocrinology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract
Context: Age at diagnosis has been identified as a major determinant of thyroid cancer-specific survival, with older patients being at higher risk for mortality, but the association of age with risk of recurrence has not been studied to date. Objective: To examine the effect of a patient's age on response to therapy and disease-specific mortality in a cohort of thyroid cancer patients at high risk of recurrence, as defined by the American Thyroid Association (ATA) risk stratification system. Design: Retrospective cohort study of 320 patients, median age 49.3 years, with follicular cell-derived thyroid carcinoma classified at ATA high risk and followed for a median of 7 years. Main Outcome Measures: Association of age with response to therapy, overall mortality, disease-specific mortality, and timing of metastases. Results: Age was a major determinant of response to therapy. There was a significantly larger percentage of excellent responders among young patients (age <55) than among old patients (age ≥55), 40.3% vs 27.5%, P = 0.002, respectively, whereas the proportion of structural incomplete responders was higher in the old group compared with the young group, 53% vs 33%, P = 0.002, respectively. ATA high-risk young patients with a structural incomplete response to therapy had a significantly better disease-specific survival than old patients (74% vs 12%, P < 0.001, respectively). Conclusions: Age was a key predictor of response to therapy and disease-specific survival in ATA high-risk thyroid cancer patients. Its incorporation as a variable in the ATA risk stratification system would improve its power to predict response to therapy as well as mortality.
Context: Age at diagnosis has been identified as a major determinant of thyroid cancer-specific survival, with older patients being at higher risk for mortality, but the association of age with risk of recurrence has not been studied to date. Objective: To examine the effect of a patient's age on response to therapy and disease-specific mortality in a cohort of thyroid cancerpatients at high risk of recurrence, as defined by the American Thyroid Association (ATA) risk stratification system. Design: Retrospective cohort study of 320 patients, median age 49.3 years, with follicular cell-derived thyroid carcinoma classified at ATA high risk and followed for a median of 7 years. Main Outcome Measures: Association of age with response to therapy, overall mortality, disease-specific mortality, and timing of metastases. Results: Age was a major determinant of response to therapy. There was a significantly larger percentage of excellent responders among young patients (age <55) than among old patients (age ≥55), 40.3% vs 27.5%, P = 0.002, respectively, whereas the proportion of structural incomplete responders was higher in the old group compared with the young group, 53% vs 33%, P = 0.002, respectively. ATA high-risk young patients with a structural incomplete response to therapy had a significantly better disease-specific survival than old patients (74% vs 12%, P < 0.001, respectively). Conclusions: Age was a key predictor of response to therapy and disease-specific survival in ATA high-risk thyroid cancerpatients. Its incorporation as a variable in the ATA risk stratification system would improve its power to predict response to therapy as well as mortality.
Authors: R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha Journal: Thyroid Date: 2010-10-29 Impact factor: 6.568
Authors: D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke Journal: Eur J Cancer Date: 1979-08 Impact factor: 9.162
Authors: Mousumi Banerjee; Daniel G Muenz; Joanne T Chang; Maria Papaleontiou; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2014-07-17 Impact factor: 5.958
Authors: Elizabeth S Duke; Amy K Barone; Somak Chatterjee; Pallavi S Mishra-Kalyani; Yuan-Li Shen; Emasenyie Isikwei; Hong Zhao; Youwei Bi; Jiang Liu; Nam Atiqur Rahman; Emily Wearne; John K Leighton; Maritsa Stephenson; Idara Ojofeitimi; Barbara Scepura; Abhilasha Nair; Richard Pazdur; Julia A Beaver; Harpreet Singh Journal: Clin Cancer Res Date: 2022-10-03 Impact factor: 13.801
Authors: Juan J Díez; Emma Anda; Victoria Alcazar; María L Isidro; Cristina Familiar; Miguel Paja; Patricia Rojas Marcos; Begoña Pérez-Corral; Elena Navarro; Ana R Romero-Lluch; Amelia Oleaga; María J Pamplona; José C Fernández-García; Ana Megía; Laura Manjón; Cecilia Sánchez-Ragnarsson; Pedro Iglesias; Julia Sastre Journal: Endocrine Date: 2022-05-18 Impact factor: 3.925